To The Moon

UNH Q3 Earnings Preview: Will the Medical Cost Dilemma See Relief?

Estimated Q3 2025 revenue: $113.07 billion, a 12.15% year-over-year increase;

Estimated EPS: $2.459, a 62.23% year-over-year decrease.

Key trends in the health insurance industry this year:

Medical Cost Inflation and Utilization Rebound: Significant increase in medical utilization among seniors and the general population, driving up medical costs. Particularly sharp increases in outpatient, orthopedic surgery, and outpatient infusion expenditures. Additionally, the emergence of new high-cost therapies (cell and gene therapies) has put short to medium-term pressure on insurance payouts.

Medicare Advantage Policy Adjustments: The U.S. federal government implemented several policy changes to Medicare Advantage plans, significantly impacting the industry landscape. The reform of the risk adjustment model (V28) has led to reduced government subsidies for health insurers. Additionally, stricter star rating standards have resulted in lower plan ratings for several insurers, meaning fewer members will be eligible for quality bonuses in 2026. Moreover, enhanced regulatory scrutiny has led to more stringent checks on MA plan billing accuracy and service approval processes.

Technology and Service Model Innovation: The health insurance industry is generally looking to technology and model innovation to alleviate cost pressures, with particular hope placed on digital health and AI applications. AI is being used to improve claims review, medical management, and other processes to reduce waste and operational costs while enhancing patient and physician experiences.

Based on these industry trends, $UnitedHealth(UNH)$   faces the same challenges as its peers. For UnitedHealthcare and Optum, the two core businesses, Q3 earnings should focus on the following key points:

UnitedHealthcare Business: Membership Growth and Pressures Coexist

~Membership and Revenue: Steady revenue growth is expected, primarily driven by membership numbers. However, it's worth noting that in Q2, the company lowered its full-year Medicare Advantage membership growth expectations from 800,000 to 650,000. With 505,000 new MA members added in the first half, Q3 MA membership growth is expected to slow significantly.

~Costs and Profits: The core issue is the Medical Loss Ratio (MLR). Whether the main factors behind Q2's high 89.4% MLR - higher-than-expected medical service utilization in Medicare Advantage plans and ongoing federal Medicare funding cuts - have been effectively controlled in Q3 is key to assessing whether this business can stabilize. Recent reports from $Molina Healthcare (MOH.US)$ suggest Q3 MLR has not improved; UNH's ability to use AI to improve claims efficiency and reduce unnecessary medical expenses will be crucial in mitigating profit margin decline.

Optum Health Services Business: Seeking Recovery Amid Challenges

~Optum Health (Medical Services): This is one of the main risk points for Q3. Profit margins declined significantly in Q2, mainly due to increased medical activity, federal Medicare funding cuts, and underestimation of the V-28 risk model transition. UNH has implemented a series of measures in Q3, such as scaling back expansion plans and strengthening integration and standardization of medical facilities. Whether Optum Health revenue has stabilized and if there are signs of operational loss mitigation will be key focus areas.

~Optum Rx (Pharmacy Benefit Management/PBM): This business is viewed as a profit stabilizer for the quarter. In Q2, this division achieved significant revenue growth. The market expects it to maintain double-digit revenue growth and partially offset high cost pressures in the insurance business through scale effects and improved margins. However, attention should be paid to the gradual implementation of Trump's "Most Favored Nation Pricing" policy this month, with several pharmaceutical companies signing price reduction agreements with the TrumpRX platform, potentially affecting Optum Rx's profit performance.

~Optum Insight (Data and Technology): Expected to continue providing stable revenue and profit contributions.

Management Outlook and Confidence Rebuilding

~After withdrawing full-year guidance in Q2, the market eagerly anticipates clearer 2025 full-year profit trajectory in the Q3 report, and possibly outlook for profit growth recovery in 2026.

~Investors should closely monitor the management call for the latest judgments on medical cost trends, premium and product adjustments, specific progress on cost control measures, and strategies for addressing regulatory risks (such as the Department of Justice investigation).

United Health Options Chain Analysis

UnitedHealth's options data leans bullish near-term but we also saw notable bearish hedge from unusual options acitvity.

It show elevated implied volatility at 44.31%, significantly above its historical volatility of 21.51%, indicating heightened expectations around earnings. The put/call ratio of 0.49 reflects a bullish sentiment among traders.

Open interest expired in this and next Firday is concentrated at the $380 and $400 strike with heavy call volume, suggesting this level is a key resistance target. Overall OI leans bullish with 79.28K calls versus 57.67K puts. High IV percentile of 80% implies expensive options premiums ahead of the report. Traders appear positioned for a potential upside move post-earnings, though volatility crush risk remains elevated after the event.

Notable Bearish Hedge: A large premium ($26.32M) paid for a long deep out-of-the-money Put ($600, expiring Jan 2026) signals institutional hedging against tail risks.

Conclusion

In summary, UnitedHealth is currently navigating a crucial period of transformation and adjustment. Despite short-term financial pressures, the company's fundamental strengths as an industry leader remain intact. These include a robust medical membership base exceeding 50 million, vertically integrated service capabilities (spanning insurance, healthcare, pharmacy, and data), increased institutional ownership, and a strong track record of cash flow generation and shareholder returns. All these factors continue to underpin UnitedHealth's long-term value proposition.

However, the evolving industry landscape necessitates that $UnitedHealth (UNH.US)$ accelerate its adaptation. The upcoming third-quarter earnings report will provide the market with clearer insights into this healthcare giant's adjustment process. The key question remains: Is UnitedHealth on the path to a stable recovery, or does it require more time to fully adapt to the new environment?

Risk Factors:

1)Unexpectedly high increases in medical cost trends

2)Potential fines or business restrictions from the Department of Justice

3)Comprehensive implementation of drug pricing policies adversely impacting the PBM business

4)Management instability affecting strategic execution

@TigerStars  @CaptainTiger  @TigerWire  @Daily_Discussion  @Tiger_chat  @Tiger_comments  @MillionaireTiger